I'll research DVA (DaVita) before writing the earnings preview. Let me start by gathering recent filings, transcripts, and news.I have the most recent earnings materials. Let me read the Q1 2026 earnings call and release, plus check for recent news and prior quarter context.Let me get the Q4 2025 call for context on initial 2026 guidance and the cyber incident, plus recent stock price and news.The stock has roughly doubled year-to-date. Let me check recent news to understand the drivers and any specific setups going into the print.I have enough to write a comprehensive preview. Let me compile the key figures and draft.Here is the earnings preview.
The single most important framing for this print is the chart. DVA has roughly doubled year-to-date (≈$114 on Jan 2 to ~$234 on Aug 3, +104%), with two explosive post-earnings gaps doing most of the work: +21% after Q4 2025 (Feb 3) and +23.5% after Q1 2026 (May 6). Both quarters featured large beats plus guidance raises.
The problem heading into Q2: the stock has outrun the sell side. Published price targets cluster in the ~$199–$217 range with a "Hold" consensus — i.e., the shares are trading at or above most targets. That means the bar is high and the risk/reward is more two-sided than the recent momentum suggests. A "good but in-line" quarter may not be enough; investors are effectively pricing in another beat-and-raise.
Consensus for Q2: roughly $3.88–$4.01 adjusted EPS on ~$3.5B revenue (estimates vary by source). This is consistent with the company's own phasing: FY26 adjusted EPS guidance midpoint is ~$14.65, Q1 delivered $2.87 (~20% of the year), leaving ~$3.93 average across the three remaining quarters, with management guiding OI to be roughly evenly split across Q2/Q3/Q4 (and IKC weighted to Q4).
This is 85%+ of the story. In Q1, DaVita beat on all three legs simultaneously — volume, revenue per treatment (RPT), and cost per treatment — which is what drove the raise and the stock. The question for Q2 is durability.
Volume — the key upside variable. - Management raised full-year treatment growth from ~flat to +25–50 bps at Q1, split roughly half underlying improvement / half patient transfers from Fresenius clinic closures. - Modeling note management gave: they saw ~half of expected Fresenius new starts by end of Q1 and expected the other half in Q2, for ~two-thirds of a full year of those starts. So Q2 is the quarter the Fresenius benefit should be most visible. Watch treatments-per-normalized-day, which sat at +40 bps in Q1 and is expected to build toward +50–75 bps for the year. - Mortality is the swing factor for the multi-year volume thesis. Q1 mortality came in slightly better than forecast (not flu-driven, "underlying"), but management explicitly declined to call it a durable trend. Any commentary confirming lower mortality/missed treatments would be a meaningful positive, since it underpins the path back to their stated ≥2% long-term volume growth (which they don't expect to fully materialize until ~2029).
Revenue per treatment (RPT). - Q1 RPT was very strong (+~4% y/y, $417.59), but management attributed ~$6 of that to timing and reiterated the full-year guide of +1–2%. - The key forward dynamic: they expect commercial mix to decline over the course of the year, pressuring RPT and bridging down from the elevated Q1 level. As of the Q1 call (through April), that mix erosion had not yet shown up — so Q2 is the first real test of whether the feared mix headwind is materializing.
Cost per treatment. - Q1 patient care cost per treatment was better than expected on labor productivity, which management said it expects to sustain. Watch whether productivity gains hold. - G&A grew ~13% y/y on IT/technology and AI investment (ScheduleHub, EMR/data platform). Management's framing: don't optimize the "geography" of the P&L — judge total cost, where the 5-yr CAGR is ~2.6%. Full-year total-cost guide is +1.25–2.25%. Expect continued elevated G&A; the pushback risk is if tech spend outpaces the benefits investors can see.
This is the most-watched macro risk for DaVita and the reason to listen closely to Q2. - Management guided a ~$40M FY26 headwind from expiring enhanced premium tax credits (with larger $70M in 2027, $10M in 2028). At Q1 they said open enrollment was trending slightly favorable vs. that $40M — but held the number, because the real data (effectuation/payment rates and, critically, the mix of incoming patients) plays out over the year. - A partial offset: a shift toward lower-tier bronze plans, which carries higher patient out-of-pocket and a modest RPT headwind. - Q2 is when payment/effectuation data starts to firm up. An explicit reduction of the $40M headwind would be a clear positive; any sign that the incident (new-patient) mix is deteriorating would be a negative for the 2027 setup.
Given the momentum, expectations lean toward another raise. Current FY26 guidance (raised at Q1): - Adjusted operating income: $2.15B–$2.25B - Adjusted EPS: $14.10–$15.20 - Free cash flow: $1.0B–$1.25B (notably not raised at Q1 despite the OI raise — management cited FCF's wider variability, so don't read a non-raise there as negative)
The risk is asymmetric: with the stock above targets, another modest raise may be "priced in," while a failure to raise (or any hint that Q1's beat was timing/pull-forward) could trigger profit-taking.
This is a core part of the EPS-compounding story (FY26 EPS is guided +33% y/y, driven by OI growth and share-count reduction). - Aggressive buybacks: 3.0M shares in Q1 ($403M @ $133.70) plus 2.0M more since quarter-end (@ $149.81), including formulaic purchases from Berkshire Hathaway that keep Berkshire's stake at/below 45%. Note the average repurchase prices are well below today's ~$234 — so recent buybacks are increasingly expensive, a watch item. - Leverage 3.34x, squarely inside the 3.0–3.5x target. Net debt ~$10B. Reminder: DVA carries a negative book equity position — normal given years of buybacks, not a red flag. - Debt expense was revised to stay ~flat y/y (higher rates + more buybacks offsetting refinancing benefit).
Bull case: Fresenius transfers hit their peak quarter; underlying mortality keeps improving; ACA headwind trending below $40M; labor productivity sustains; another guidance raise; buyback keeps shrinking the share count. All three trilogy legs beat again.
Bear case: Q1's strength was partly timing (RPT ~$6) and pull-forward; commercial mix erosion finally shows up in Q2 RPT; G&A/tech spend keeps climbing; the 2027 ACA cliff ($70M) looms; and — most importantly — the stock already reflects a beat-and-raise while trading above most price targets, leaving little margin for error.
Note on sourcing: figures on volume/RPT/cost, guidance, IKC, ACA, capital allocation, and management commentary are drawn from DaVita's Q1 2026 and Q4 2025 earnings releases and call transcripts; stock levels are from historical price data; and consensus estimates (~$3.9–$4.0 EPS, ~$3.5B revenue) and price-target/rating color are from third-party market sources and should be treated as approximate.